Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors

Table 7 Characteristics and outcome of canine patients treated with chemotherapy alone for refractory cancers

PATIENT	AGE	TUMOR	PREV. TREATMENT	THERAPY	OUTCOME (MONTHS)
MIXED	11	LSA	MADISON + MOPP	MADISON	PD 1
SETTER	6	ALL	MADISON + MOPP	MADISON	PD 1
BOXER	9	SKIN CARCINOMA	DOXORUBICIN CARBOPLATIN	CARBOPLATIN	PR 2
WHWT	8	LSA	MADISON + MOPP	MADISON	PR 1
ROTTW	7	LSA	MADISON + MOPP	MADISON	PR 3
GERMAN	9	LSA	MADISON + MOPP	MADISON	PD 1
SHEPHERD			MOPP
LABRADOR	9	LSA	MADISON + MOPP	MOPP	PD 2
MIXED	10	MAMMARY CARCINOMA	DOXORUBICIN CARBOPLATIN	DOXORUBICIN	PR 1
DOGO	10	LIPOSARCOMA	DOXORUBICIN CARBOPLATIN	CARBOPLATIN	PD 1
MIXED	10	MAMMARY CARCINOMA	DOXORUBICIN CARBOPLATIN	CARBOPLATIN	PR 2

Abbreviations: ALL: acute lymphocytic leukemia; LSA: lymphosarcoma; MOPP: mechlorethamine, oncovin (vincristine), prednisone, procarbazine; WHWT: west highland white terrier.
Drugs schedule: doxorubicin 30 mg/m² every 21 days (pending hematological, cardiac and renal evaluation) up to 6 doses, carboplatin 210 mg/m² every 21 days, mitoxantrone 6 mg/m² every 21 days. For Madison and MOPP protocols see table 4 and 5.

ISSN: 1479-5876